Table 9 Selected first-line results from phase 2 trials in MET exon 14 skipping NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Treatments | Objective response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|---|
PROFILE 1001 | NCT00585195 | Crizotinib | 25 | NR | NR |
VISION | NCT02864992 | Tepotinib | 44.9 | 8.5 | NR |
Geometry-Mono-1 | NCT02414139 | Capmatinib | 68 | 9.7 | NR |